Recent experimental evidence supports the role of glucocorticoids in the neuroendocrine control of food intake and energy expenditure. In particular, glucocorticoids promote food consumption directly through stimulation of NPY and inhibition of CRH and melanocortin release. CRH and NPY are also functionally linked by a mutual regulation. CRH is anorexigenic when secreted acutely while it exerts the opposite effect when, upon sustained secretion, it stimulates the hypothalamo ± pituitary ± adrenal (HPA) axis. The orexigenic effects of glucocorticoids are counteracted by a steroid-induced rise in leptin levels that closes a regulatory loop regarding food consumption. Furthermore, glucocorticoids may alter body fat distribution, increasing truncal adiposity both directly and by inhibition of growth hormone secretion. No clearcut alterations of the HPA function are apparent in obesity as a whole. However, subtle and speci®c abnormalities may be noted in subsets of obese patients. Indeed, obesity, mostly visceral type, is associated with an increased cortisol clearance and 11-b b hydroxysteroid dehydrogenase activity in the omental fat. In the same vein, an increased cortisol rise following a mixed meal has been observed in obese subjects. Finally, it has been proposed that adrenal incidentalomas, often characterized by enhanced cortisol secretion, might be a clinical expression of the X syndrome. International Journal of Obesity (2000) 24, Suppl 2, S77±S79
Evidence that glucocorticoids play a potential role in development of obesity is accumulating rapidly. Glucocorticoid excess is almost invariably associated with a typical truncal fat accumulation. An exception is represented by patients with anorexia nervosa who, in spite of an often marked hypercortisolism, do not develop Cushingoid features. In this regard, the underlying mechanisms are not yet fully elucidated, however, recent ®ndings of our laboratory tend to exclude a glucocorticoid resistance and favour a lack of metabolic substrates as a possible cause. 1 Glucocorticoids promote food consumption both directly and through stimulation of NPY and inhibition of CRH release. 2 ± 4 In the hypothalamus glucocorticoids may bind to type I receptors, speci®c for mineralocorticoids, tonically activated and sensitive to low concentrations of glucocorticoids, and to type II receptors, speci®c for glucocorticoids, and only phasically activated by higher concentrations of glucocorticoids. Binding of these receptors is followed by enhanced food consumption with preferential selection of fat (type I receptor) or carbohydrates (type II receptor). 5 In rats, treatment with dexamethasone results in a signi®cant increase in expression and content of NPY in the hypothalamus and especially in the paraventricular nucleus (PVN), where CRH neurons are located. Notably, the effects of dexamethasone are abolished by administration of insulin. 6 On the other hand, i.c.v. injection of CRH for 7 days in obese faafa rats has been shown to inhibit the hypothalamic expression of NPY. 7 Taken together, these ®ndings indicate that glucocorticoids stimulate NPY secretion by inhibition of CRH release. Recently it has also been shown that mice genetically de®cient in NPY exhibit an attenuated rise in CRH-mRNA concentrations in the PVN in response to fasting. 8 These data point to a direct role of NPY in mediating fast-induced CRH secretion.
Thus, a classical feedback regulatory loop appears to exist between CRH and NPY. CRH exerts an anorexigenic effect by inhibiting the release of NPY and other hypothalamic neuropeptides, such as GHRH and somatostatin, while enhancing the feeding drive by activating the pituitary ± adrenal axis and eliciting the pituitary release of opioids and, according to recent data of our laboratory, 9 also of galanin ( Figure 1 ). It may be hypothesized that acute CRH release inhibits food intake while chronic CRH secretion results in a net orexigen effect.
The inhibitory in¯uence of glucocorticoids on GH secretion deserves a mention. The paradigm of this is well represented in patients with Cushing's syndrome. 10 However, it is noteworthy that also in patients with simple obesity both spontaneous and stimulated GH secretion are markedly impaired. 10 ± 14 The high circulating levels of FFA probably play a major role in the hyposomatotropism of obesity as indicated by the marked increase of the spontaneous and GHRH-induced GH secretion provoked by acipimox, an antilypolitic drug that lowers plasma FFA levels. 12 ± 14 The increased plasma levels of the free fraction of IGF-1, recently demonstrated in obese subjects, might be an additional inhibitory mechanism of GH secretion. 15 Furthermore, since leptin is able to elicit GH release in the rat, 16 the leptin resistance in obesity might contribute to further impair somatotrope function.
This action is at least partially mediated by inhibition of NPY, 17, 18 known to downregulate GH secretion. 19 Leptin plays an important role in the functional relationship between glucocorticoids and the neuroendocrine system. While glucocorticoid administration promotes ob gene expression and elevates its product in plasma, 20 ± 22 leptin has been shown to negatively feedback at the adrenal level, inhibiting both basal and ACTH-stimulated cortisol secretion. 23, 24 Furthermore, leptin exposure enhances spontaneous 25 ± 27 but inhibits stimulated 28 CRH synthesis and release.
In summary: (a) increasing experimental evidence suggests the presence of a classical feedback loop between glucocorticoids, which stimulate leptin production, and leptin, which inhibits glucocorticoid secretion; (b) in the acute setting, leptin exerts a net anorexigenic effect both by stimulating CRH and by inhibiting NPY release, while in the more chronic setting, leptin prevents the activation of the HPA axis; and (c) at least in the experimental animal model, leptin promotes GH secretion via inhibition of NPY release.
A condition of leptin resistance in obese patients might therefore induce: (a) an impairment of CRH and a stimulation of NPY release leading to increased feeding drive; (b) a chronic disinhibition and overdrive of the HPA axis; and (c) an impaired GH release.
Recent data suggest that melanocortins may play a key role in modulating the interactions of leptin with the neuroendocrine system. 29, 30 These peptides, which are cleaved from proopiomelanocortin in neurons located in the arcuate nucleus, induce c-fos expression in the PVN and exert a marked anorexigenic effect. The melanocortin neurons display leptin receptors and project to the PVN where the CRH-producing neurons are endowed with melanocortin receptors. On this basis, a leptin ± melanocortin ± CRH anorexigenic pathway might be postulated. 29, 30 Other complex neuroendocrine interactions underline the leptin role in feeding behaviour and nutritional homeostasis.
Fasting-induced leptin decrease results in the activation of the NPY anabolic pathway with enhanced food consumption and reduced energy expenditure and in the inhibition of melanocortin ± CRH catabolic pathway with a decrease of the anorexigenic effect of these peptides and of energy expenditure (Figure 2 ). These effects of leptin are ampli®ed by glucocorticoids that increase following leptin reduction and act via NPY stimulation and melanocortin ± CRH inhibition. 31 While the existence of close interactions between glucocorticoids and the neuroendocrine system is well established, the secretion and metabolism of glucocorticoids in obesity is still under debate. The HPA axis does not display consistent alterations in obesity as a whole. However, subtle and speci®c abnormalities of the HPA axis may be noted in subsets of obese patients. 32, 33 Recently, Bujalska et al 34 demonstrated an increased production of cortisol from cortisone in the omental fat of both obese and normal subjects; this was due to an higher activity of the 11-b hydroxysteroid dehydrogenase 1 (or 11-b hydroxysteroid reductase) prevailing over that of 11-b hydroxysteroid dehydrogenase 2. Thus, visceral obesity might re¯ect Cushing's disease of the omental fat. 34 Similarly, the observation of a more marked ACTH and cortisol rise occurring after a noon mixed meal in obese than in lean subjects 35 favours the view of an enhanced cortisol secretion in the former. Lastly, the increased prevalence of obesity among patients with adrenal incidentaloma 36, 37 and the experimental evidence of a mitogenic effect of insulin on the adrenocortical cells 38 have led to the proposal that adrenal incidentalomas are a clinical expression of the metabolic or X syndrome. Glucocorticoids and neuroendocrine function F Cavagnini et al
